



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Chalifour *et al.*  
ASSIGNEE : Neurochem Inc.  
SERIAL NUMBER: 09/724,842 EXAMINER : Not yet assigned  
FILING DATE : November 28, 2000 ART UNIT : Not yet assigned  
FOR : VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
AND AMYLOID RELATED DISEASES

June 29, 2001  
Boston, Massachusetts

BOX IDS  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

- ☒ Information Disclosure Statement (3 pages);
- ☒ Modified Form 1449/PTO duplicate copy (1 page);
- ☒ Limited Recognition Under 37 CFR § 10.9(b) (1 page);
- ☒ References A1-A6; B1-B10; and
- ☒ Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

No fee is believed to be due. However, if any fees are to be assessed, the Commissioner is hereby authorized to charge the balance due to the undersigned's account, Deposit Account No. 50-0311, Reference No. 14445-501 (NCHEM-1). A duplicate copy of this transmittal letter is enclosed.


Respectfully submitted,

A handwritten signature in black ink, reading "Shelby J. Walker". The signature is fluid and cursive, with a horizontal line drawn underneath it.

Ivor R. Elrif, Reg. No. 39,529  
Michel Morency, Limited Recognition  
Shelby J. Walker, Reg. No. 45,192  
Attorney(s) for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Express Mail Label No.: EF7 19945US  
Date of Deposit: June 29, 2001

Attorney Docket No. 14445-501 (NCHEM-1)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Chalifour *et al.*  
ASSIGNEE : Neurochem Inc.  
SERIAL NUMBER: 09/724,842 EXAMINER : Not yet assigned  
FILING DATE : November 28, 2000 ART UNIT : Not yet assigned  
FOR : VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S AND  
AMYLOID RELATED DISEASES

June 29, 2001  
Boston, Massachusetts

BOX IDS  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

**U.S. Patent Documents:**

5,985,242	11/16/99	Findeis et al
5,688,651	11/18/97	Solomon
5,721,130	2/24/98	Seubert et al
5,837,672	11/17/98	Schenk et al
5,891,991	4/6/99	Wasco et al
5,851,996	12/22/98	Kline

**Foreign Patent Documents:**

WO	00/26238	Imperial College Innovations Limited	11 May 2000
WO	95/12815	The Research Foundation of State University of New York	11 May 1995
WO	98/22120	The Wistar Institute of Anatomy & Biology	28 May 1998
WO	98/05350	Milkhaus Laboratory, Inc.	12 February 1998
WO	99/58564	Gaudernack, Gustav	18 November 1999

APPLICANTS: Chalifour  
U.S.S.N.: 09/724,842

WO	00/43039	During, Matthew, John	27 July 2000
WO	99/27944	Athena Neurosciences, Inc.	10 June 1999
WO	99/60024	The University of Tennessee Research Corporation	25 November 1999
WO	99/60021	Yeda Research and Development Co., Ltd., and Mcinnis, Patricia, A.	25 November 1999
WO	99/27949	Brigham and Women's Hospital	10 June 1999

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to

APPLICANTS: Chalifour *e*  
U.S.S.N.: 09/724,842

Deposit Account No. 50-0311, Reference No. 14445-501 (NCHEM-1). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,



---

Ivor R. Elrifi, Reg. No. 39,529  
Michel Morency, Limited Recognition  
Shelby J. Walker, Reg. No. 45,192  
Attorney(s) for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRA 1512717v1